Oslo, 10 May 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team will discuss data from the abstract of a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting at a series of investor events in May, beginning with a live corporate webcast on Thursday May 20, 2021.
The abstract is titled “A Phase I Clinical Trial Investigating the Telomerase Vaccine UV1 in Combination with Pembrolizumab in Patients with Advanced Melanoma”. It provides an overview of the open-label, single-arm study investigating the safety and tolerability for the combination of Ultimovacs’ universal cancer vaccine, UV1, with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma.
The ASCO abstract will be made available on the company website on Wednesday, May 19th at 23:00 CEST and will be presented at the ASCO 2021 Annual Meeting to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The full poster presentation from the ASCO Annual Meeting will be available on the Ultimovacs website on 4 June 2021.
Details of the investor events:
Event: Live Corporate Webcast
Date/Time: Thursday May 20, 10:00 CEST
Presenter: Carlos de Sousa, CEO: Jens Bjørheim, CMO. The webcast will be available on the company website, and it will be possible to post questions during the presentation through the webcast.
Event: Radforsk’s Podcast RADIUM
Date/Time: Thursday May 20, 14:00 CEST
Presenter: Carlos de Sousa, CEO. The podcast will be available on the company website.
Event: 7th Annual Immuno-Oncology Innovation Forum, SACHS associates (18-20th May, 2021)
Date/Time: Thursday May 20, 19:25 CEST
Presenter: Carlos de Sousa, CEO. Meeting link available on Ultimovacs’ website.
Event: ABG Sundal Collier Life Science Summit 2021 (held virtually)
Date/Time: Tuesday May 25, 16:00 CEST
Presenter: Carlos de Sousa, CEO
Event: Biostock Life Science Spring Summit (held virtually)
Date/Time: May 26-27
Presenter: Carlos de Sousa, CEO. Meeting link available on Ultimovacs’ website.